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An evaluation of storage time for
dithiothreitol-treated reagent cells
CD38 monoclonal antibodies are therapeutic agents
used in the treatment of patients with multiple mye-
loma who have not achieved remission with traditional
treatment regimens. Daratumumab (Darzalex; Janssen
Biotech, Inc.) is currently approved by the US Food and
Drug Administration for use in patients with multiple
myeloma. It is known that antibodies to CD38 (cluster
of differentiation 38 [cyclic adenosine diphosphatase
ribose hydrolase]) will interfere with serologic tests by
causing positive indirect antiglobulin tests (IATs).1
Because the drug will be pan-reactive with IAT screen-
ing and panel cells, clinically significant alloantibodies
may be masked. Dithiothreitol (DTT) is a reducing
reagent that effectively breaks disulfide bonds, disrupt-
ing the antigenic binding sites of the CD38 molecule on
red blood cells. DTT-treated cells are a valuable reagent
used to assess alloantibody production in patients
undergoing anti-CD38 treatment. Some blood group
systems, such as Lutheran, Kell, Cartwright, Scianna,
Dombrock, Landsteiner Weiner, Cromer, Knops, Indian,
and John Milton Hagen groups, are destroyed or weak-
ened with DTT treatment.2 Because Kell is a common
clinically significant antibody and cannot be excluded
using DTT-treated cells, we issue units that are negative
for KEL1 or KEL2 based on the patient’s phenotype. To
have DTT reagent cells available routinely, we per-
formed a validation study to determine the storage life
of DTT-treated reagent cells when stored in red blood
cell support solution (Hemo Bioscience).
The study was conducted over a period of 12 days.
Twelve samples were treated with 0.2-M DTT for evalua-
tion. The samples selected included three different
reagent cells (C1c2E2, C2c1E1, and C2c1E2) from
four different manufacturers (Ortho Clinical Diagnostics;
Immucor, Inc.; Quotient; and Bio-Rad Laboratories, Inc.).
Procedures used for the preparation of 0.2-M DTT
reagent and the treatment of red blood cells are
described in Judd’s Method in Immunohematology.3 Start-
ing volumes of 10.5-mL treated cells and 0.6-mL
untreated cells were diluted to 3 to 5% in red blood cell
support solution. Samples were stored in a refrigerator
set at 2 to 88C. Daily evaluation of hemolysis was per-
formed using a standard chart to visually grade hemoly-
sis (Fig. 1).4 Antigen integrity was assessed using routine
antisera from Ortho Clinical Diagnostics: anti-C, anti-c,
anti-E, and Immucor anti-k. Reagent cell performance
was assessed with a positive control and a negative con-
trol. The positive control consisted of an Ortho confi-
dence antibody diluted to 0.9% with normal saline, and
a negative control was prepared from Immucor 22%
bovine albumin diluted to 6 to 8% with phosphate-
buffered saline, pH 7.1. Indirect antiglobulin testing was
performed using Ortho column agglutination (gel), and
tube testing was carried out with Immucor polyethylene
glycol (PEG) additive and with no additive (saline
method). The results were compiled, and these data
were used to determine whether the reagent cells had
maintained potency for the evaluation period. At Day 9,
1 mL of supernatant was removed to correct concentra-
tion of cells back to 3 to 5%.
The expected evaluation criteria for this study were:
1. Observable hemolysis less than 200 mg/dL;
2. k (KEL2) antigen tests negative;
3. D antigen test 21 or greater;
4. Gel, PEG, and saline tests are 11 or greater with
dilute confidence antibody; and
5. Gel, PEG, and saline tests are negative with 6% albumin.
Our findings are summarized in Table 1. Although
hemolysis levels for two samples reached 200 mg/dL on
Day 7, we noted that hemolysis did not affect the
expected performance of reagent cells. The study ended
at Day 12 with one-third of the samples reaching
200 mg/dL hemolysis. Although the reagent cells tested
from 0 to 11 for k (KEL2) antigen after DTT treatment,
the cells successfully avoided anti-CD38 reactivity when
tested with patient plasma. Antigen testing for k (KEL2)
remained 11 or less throughout the study. Satisfactory
D antigen reactivity remained on samples with 31 to
41 throughout the study. Gel and tube testing with PEG
or with no additive was greater than 11 with dilute
confidence antibody (positive control) throughout the
test evaluation. No false-positive reactions were
observed with the 6 to 8% albumin negative control.
In conclusion, our study demonstrates that DTT-
treated red blood cells stored in red blood cell support
solution can maintain potency for up to 12 days.
Because the number of samples that yielded unsatisfac-
tory hemolysis results continually increased after 7
days, we decided to use a 7-day expiration for DTT-
treated cells. Satisfactory results were demonstrated
with positive and negative controls for all test methods
(column agglutination and tube tests with PEG and no
additive). D antigen integrity was maintained. As an
adjunct to this validation, we evaluated Duffy antigens
(Fya and Fyb) after DTT treatment and observed that
one of 10 samples had diminished antigen expression
after treatment; thus, we recommend including tests for
Fya and Fyb antigens after preparing DTT-treated
reagent cells. We have found that these reagent cells are
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useful in avoiding the pan-reactivity observed in
patients who receive daratumumab when assessing allo-
antibody formation.
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Fig. 1. This bar graph represents the
visual grading of hemolysis with
approximate levels of 0, 25, 50, 100,
and 200 mg/dL for the 12 DTT-treated
samples. The solid black line illustrates
the mode for daily hemolysis.
TABLE 1. Results for data collected on the initial, middle, and final day reported
Test Day 0 Day 7 Day 12
Hemolysis grading
Untreated cells, mg/dL 0 0 0
DTT-treated cells, mg/dL 0 10 of 12< 200 8 of 12< 200
Antigen testing of DTT-treated cells
Anti-k 8 of 1250 8 of 1250 8 of 1250
4 of 12 11 4 of 12 11 4 of 12 11
Anti-C 12 of 125 41 12 of 125 41 3 of 125 41
9 of 12531
Anti-c 12 of 125 41 12 of 125 41 12 of 125 41
Anti-E 12 of 125 41 12 of 125 41 12 of 125 41
IAT test performance of DTT cells with control sera
Column agglutination (gel)
Positive control 21 to 41 21 to 41 21 to 41
Negative control 0 0 0
Polyethylene glycol (PEG)
Positive control 21 to 41 21 to 41 21 to 41
Negative control 0 0 0
No additive (saline method)
Positive control 21 to 41 21 to 41 21 to 41
Negative control 0 0 0
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